Oct 21, 2026 October corporate presentation updates the development windows Headline · Source: company release

Nasdaq: $PDSBDated financial statementsOperating and funding watchpointsExecution risk

PDSB Stock Hub: PDS Biotechnology News, PDS0301 and Conditional Funding

The PDS0301 strategy combines an early colorectal signal with conditional financing. Trial confirmation, a registrational protocol and actual funding determine what follows. The October 30 regular-session close was $1.44 (-7.10% versus October 29).

Last updated: November 2, 2026Market reference: October 30, 2026 regular-session closeFinancial period: June 30, 2026; September placement and share structure separately datedResearch archive: October 29, 2026; currency USD unless stated

Full research report · PDF

PDS Biotechnology ($PDSB), research as of October 29, 2026

14 pages covering the dated business, operating milestones, financial resources, capital structure, risks, scenarios, sources and FAQ. This is a dated research snapshot; the hub follows later developments. For personal use only: redistribution prohibited.

Get the report (PDF)

Next existing clinical window

Q4 2026 / Q1 2027 · interim prostate cancer data

The October corporate presentation places interim prostate cancer data in Q4 2026/Q1 2027 and final colorectal data in Q1/Q2 2027. These are company windows, not fixed release days. Primary source

The separate $11M financing tranche depends on submission of the agreed registrational protocol and closing conditions. A clinical update alone does not satisfy every financing condition.

PDS Biotechnology PDSB daily stock chart — Daily chart $PDSB. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

PDSB stock at a glance

Close · October 30, 2026

$1.44

Regular session; -7.10% versus $1.55 on October 29.

Reported cash

$5.596M

June 30, 2026; before September PIPE · Source

Historical monthly burn

~$1.194M

Calculated H1 2026 operating average · Source

Initial PIPE closing

$11.3M gross

September 14, 2026; before debt repayment · Source

Further PIPE tranche

$11M conditional

September 2026 protocol-submission condition · Source

Common shares

81.856M

September 14, 2026; ownership filing basis · Source

Colorectal response rate

71.4% — 15/21

September 2026 update; nonrandomized · Source

Short interest

3.39M

Nasdaq, settlement October 15, 2026; 1.0 day to cover on Nasdaq’s figures · Source

Where PDS Biotechnology stands now

At June 30, 2026, PDS held $5.596 million of cash after $7.164 million of first-half operating cash use. September brought $11.3 million gross, of which approximately $4.6 million redeemed Yorkville debt; the difference is not an October cash balance. The next $11 million is conditional on the agreed PDS0301 protocol milestone and closing terms. This funding structure must support execution after the August restructuring. June Form 10-Q · September closing

The operating evidence and financing conditions remain separate tests. The colorectal evidence is nonrandomized. September gross proceeds, debt repayment and contingent funding are not a current cash balance.

The constructive case

The favorable scenario requires PDS0301’s expanded colorectal cancer signal to remain persuasive as follow-up matures, a workable registrational plan, and completion of the conditional financing. In the September 2026 presentation, the company reported a six-month response rate of 71.4%, or 15 of 21 evaluable patients, with approximately 80% survival at two years in the 22-patient cohort. These are encouraging nonrandomized observations, not proof of superiority over chemotherapy. A stronger case would combine durable results, manageable toxicity and a trial budget that the available capital can support. Source

The cautious case

The adverse scenario arises if PDS0301’s results weaken with broader enrollment or longer observation, regulatory requirements raise costs, or the contingent investment is delayed. The June 2026 accounts already carried a going-concern warning. September improved the funding position but also used approximately $4.6 million to retire the Yorkville note, so the gross PIPE proceeds were not all available for clinical work. Further capital on unfavorable terms could preserve the company while reducing the value attributable to each existing share. Source Source

Latest PDS Biotechnology news

Oct 21, 2026

October corporate presentation updates the development windows

The filed October presentation places interim prostate data in Q4 2026/Q1 2027 and final colorectal data in Q1/Q2 2027. These are company windows, while the registrational protocol financing condition remains a separate requirement.

SEC filing

Oct 20, 2026

Four directors resign; three new directors join the board

On October 18, 2026 four directors resigned from the board and its committees, effective immediately; the company said none resigned because of a disagreement. The board appointed three new directors: the chief executive of Pluvia Biotech; a former chief executive of Oxford Biomedica (2008 to 2022); and a former vice chairman and chief executive of Abraxis BioScience. It set the board at seven seats. Each new director received an option on 22,700 shares. Another director now chairs the Audit Committee, the strategic investor the Compensation Committee and the former Abraxis BioScience executive the Nominating and Governance Committee. The release says the company is advancing PDS0301 toward a Phase 3 trial in metastatic colorectal cancer and pursuing partnerships for PDS0101. Source

SEC filing

Oct 14, 2026

Resale registration filed for up to 110.0 million shares from the September placement

PDS filed a Form S-3 registering the resale of up to 110,001,540 common shares by the selling stockholders of the September 2026 private placement: 16,502,870 shares already issued, up to 73,498,156 shares from pre-funded warrants (including up to 50,000,000 issuable at the milestone closing tied to submitting a registrational PDS0301 Phase 3 protocol to the FDA) and up to 20,000,514 shares from common warrants exercisable at $0.22. The company receives no proceeds from resales, only from any cash exercise of warrants. At filing, the registration statement was not yet effective.

SEC filing

Sep 22, 2026

PDS0101 publication highlighted

PDS announces peer-reviewed oncology journal publication of VERSATILE-002. Median survival was 39.3 months in the 53-patient checkpoint-naive efficacy cohort. The nonrandomized result supports the evidence available for partnering; it does not restart the internally discontinued VERSATILE-003 trial. Source Source

SEC filing

Sep 14, 2026

Initial strategic PIPE closes

Approximately $11.3 million gross was raised, including Nant's approximately $10 million investment. The Yorkville note was fully redeemed for approximately $4.6 million. The potential additional $11 million remains linked to protocol submission and transaction conditions. Source Source

SEC filing

Aug 25, 2026

Workforce reduction disclosed

On August 25, 2026, PDS disclosed plans for a restructuring affecting about 36% of its workforce, with approximately $842,000 of expected one-time cash separation costs in the third quarter. The smaller operating structure supports the strategic reset but also changes execution capacity.

SEC filing

PDSB stock catalysts and dated watchpoints

Q4 2026 / Q1 2027 — Interim prostate cancer data window in the October presentation. Company window
Q1 / Q2 2027 — Final colorectal cancer data window. Company window
Separate conditional step — Agreed registrational protocol submission and closing conditions for the second PIPE tranche. Financing condition

Primary source · Primary source

PDS0301 colorectal cancer: the signal and its limits

The April 15, 2026 company announcement described the first nine patients in the NCI-led colorectal liver metastasis cohort: seven responses at six months, an objective response rate of 77.8%. A separate chemotherapy study reported seven responses among twenty patients. The comparison is interesting because both involved a difficult clinical setting, but the studies were not randomized against each other. It cannot isolate the incremental effect of adding PDS0301. Source

The September 2026 presentation supplies a larger update: 15 responses among 21 evaluable patients at six months, or 71.4%, and approximately 80% two-year survival in a cohort of 22. The response denominator and the survival cohort are different. The September figures are not the original nine-patient publication, and the early 77.8% figure does not represent every subsequently enrolled patient. Source

Debt and financing: what was retired, and what remains conditional

Before the Yorkville note was redeemed, the August 31 amendment filed September 4 provided for weekly ATM-proceeds notices and payment of the applicable portion within one business day, extended the note’s Nasdaq-deficiency cure period from 75 to 180 days, and required 100% of net cash proceeds from non-ATM equity or equity-linked financings to be applied to redemption within five business days. Effectiveness was conditioned on execution and payment of the September 14 installment. These are historical terms of the subsequently retired note, not continuing cash-remittance obligations. PDS Biotechnology Form 8-K filing.

The June accounts carried the Yorkville promissory note at $4.323 million net of discount, against an original $6 million face amount. It bore 10% interest and had a June 15, 2027 maturity. The September 14 filing confirms full redemption for approximately $4.6 million, including outstanding principal and interest, without an early-termination penalty. Its old maturity, cash-remittance requirements and acceleration provisions are no longer continuing obligations after that termination. Source Source

Merlintrader Health Score · $PDSB

2.00out of 5

Financial resources · 30%1.5

June 2026 cash was $5.596 million and operating burn averaged $1.194 million monthly. September’s $11.3 million gross PIPE also funded $4.6 million of debt redemption; the subsequent cash balance is not a matter of simple addition. Source Source

Catalysts · 30%2.5

The September 2026 deck gives clinical windows beginning Q4 2026/Q1 2027. The $11 million financing tranche depends on a separate registrational-protocol submission and closing terms. Source Source

Capital allocation · 20%1.5

The September 14 capital structure includes substantial pre-funded and common warrant exposure. New capital can sustain development while materially changing participation per existing share. Source Source

Trading liquidity · 10%3.0

Historical trading-access assessment retained. The October 30, 2026 regular-session close was $1.44; price alone does not establish spreads, depth or future turnover.

Operating execution · 10%2.0

September colorectal data preserve a signal, but the evidence is nonrandomized and the registrational plan remains to be executed after the August restructuring. Source Source

Assessed October 4, 2026. Weighted calculation: 1.5×30% + 2.5×30% + 1.5×20% + 3.0×10% + 2.0×10% = 2.00. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.

Red flags

Financial balances retain their reporting dates; they are not current cash.
Company targets and guidance do not establish completed execution or a regulatory outcome.
Financing, obligations and changes in the share count affect per-share economics.

PDSB Stock FAQ: PDS Biotechnology Questions Answered

When is the next PDSB stock catalyst?

PDS Biotech’s October 2026 presentation targets interim biochemically recurrent prostate-cancer data for Q4 2026/Q1 2027, followed by final colorectal-cancer data in Q1/Q2 2027. These are the next PDS0301 clinical windows, without an exact release day. A separate financing milestone depends on submission of the agreed registrational Phase 3 protocol. Clinical readout windows. Financing milestone condition.

Is PDS Biotech’s PDS0301 FDA approved?

No: as of November 2, 2026, PDS0301, formerly PDS01ADC or NHS-IL12, remains an investigational tumor-targeted IL-12 immunocytokine. Its colorectal-cancer program is generating Phase 2 evidence, while a registrational Phase 3 protocol is in design. Submission of that trial protocol would be a development milestone, rather than a marketing application. Pipeline and registrational planning.

How much cash does PDS Biotech have, and how long will it last?

PDS Biotech held $5.596 million cash at June 30, 2026, against first-half operating cash use of $7.164 million, averaging about $1.194 million monthly. That historical ratio gives about 4.7 months from June, not a current funding forecast. September’s $11.3 million gross financing, debt repayment, restructuring and continued spending change the later position. The June filing disclosed substantial going-concern doubt. Cash, operating use and going concern. September financing and debt repayment. Restructuring disclosure.

Is PDSB stock at risk of dilution?

PDS Biotech’s September 14, 2026 PIPE issued 16,502,870 common shares, 23,498,156 pre-funded warrants and 20,000,514 common warrants. Most of the pre-funded subscription price was paid at closing; the remaining exercise price is only $0.00033 per share. Their share exposure is substantial but residual exercise cash is small. The separate common warrants carry a $0.22 exercise price, and a conditional later tranche can issue additional securities. Initial securities issued. Warrant terms and conditional issuance.

When does PDS Biotech report earnings?

As of November 2, 2026, PDS Biotechnology had not announced its next financial-results date. Its latest reported financial quarter ended June 30. The prostate and colorectal data windows concern clinical results, rather than a confirmed financial-results schedule. Company announcements and reporting schedule. Latest quarterly filing. Separate clinical readout windows.

What does PDS Biotechnology do?

PDS Biotechnology develops targeted cancer immunotherapies. Its lead focus is PDS0301, a tumor-targeted IL-12 immunocytokine intended to alter the tumor microenvironment and support other cancer treatments. It also develops the Versamune platform and PDS0101 for HPV-associated cancers, for which it is pursuing externally funded development.

Has PDS Biotech received the full September PIPE financing?

No: the September 14, 2026 initial closing raised approximately $11.3 million gross; a further $11 million is conditional on a specified protocol submission and closing conditions. The milestone concerns submission to FDA of a registrational PDS0301 Phase 3 protocol designed with Nant. The potential $22.3 million total is not a reported cash balance. Initial closing. Milestone closing requirements.

Why did PDS Biotech stop VERSATILE-003?

PDS Biotech announced on August 11, 2026 that it would discontinue internally funded VERSATILE-003 and prioritize PDS0301 while seeking partnerships for PDS0101. September’s VERSATILE-002 publication concerns a different Phase 2 study, with 39.3-month median survival in the checkpoint-naive cohort. Its nonrandomized findings do not establish randomized superiority or announce a funded Phase 3 restart. Strategic refocus and discontinuation. VERSATILE-002 original trial publication.

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent analysis and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $PDSB or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.

Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.

PDSB Stock Hub: PDS Biotechnology News, PDS0301 and Conditional Funding

PDSB stock at a glance